ArticleNPJ vaccines2025
Randomized field trial of a therapeutic vaccine against Trypanosoma cruzi natural infection in dogs and correlates for efficacy.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Vaccines against chronicExpert review of vaccines · 2026Review
- Article
- Epitope mapping of vaccine antigens Tc24 and TSA1 with antibodies from Trypanosoma cruzi-infected patients.Genes and immunity · 2026Article
- Randomized field trial of a therapeutic vaccine against Trypanosoma cruzi natural infection in dogs and correlates for efficacy.NPJ vaccines · 2025Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Chagas disease, caused by Trypanosoma cruzi, is a vector-borne parasitic disease, and dogs are a major domestic host of the parasite. We performed the first randomized field trial of an immunotherapeutic vaccine among client-owned dogs with natural infections and investigated immune correlates of efficacy. Thirty one dogs with T. cruzi infection received three doses of Tc24-C4 and TSA1-C4 recombinant proteins with MPLA (N = 16) or saline control (N = 15) and were followed for six months. Therapeutic vaccination decreased parasite burden, prevented/stopped cardiac alterations measured by electrocardiographic (ECG) recordings and was safe. Vaccine treatment induced changes in T cell activation and T cell receptor (TCR) repertoire, and also inhibited the ongoing innate immune response to reduce inflammation, suggesting a complex interplay between innate and T cells. These results support the further development of a vaccine based on these antigens to prevent the progression of chronic cardiac disease from T. cruzi infection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.